Identifying factors for pembrolizumab eligibility in head and neck cancer

被引:0
作者
Miyamaru, Satoru [1 ]
Murakami, Daizo [1 ]
Nishimoto, Kohei [1 ]
Orita, Yorihisa [1 ]
机构
[1] Kumamoto Univ, Grad Sch Med, Dept Otolaryngol Head & Neck Surg, 1-1-1 Honjo,Chuo Ku, Kumamoto 8608556, Japan
关键词
Pembrolizumab; Head and neck cancer; Immune checkpoint inhibitors; Combined positive score (CPS); Survival analysis; SQUAMOUS-CELL CARCINOMA; METASTATIC HEAD; RECURRENT; CHEMOTHERAPY; CETUXIMAB;
D O I
10.1007/s00432-025-06121-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeAlthough immune checkpoint inhibitors (ICIs) are used as first-line treatments for recurrent or metastatic head and neck cancer (R/M HNC), there are many cases where the treatment is ineffective, making the assessment of efficacy crucial. In this study, we examined factors associated with the therapeutic effects of pembrolizumab.MethodsWe retrospectively analyzed 54 patients with R/M HNC treated with pembrolizumab from January 2020 to December 2022. We investigated the relationship between survival rates and various factors such as the combined positive score (CPS), histological subtypes, recurrent lesions, details of administered agents, sequence of administration, history of cetuximab use, and presence of immune-related adverse events (irAEs).ResultsThe overall survival rates at 1-, 2, and 3 years were 57.4%, 41.8%, and 32.3%, respectively. The response and disease control rates were 31.5% and 51.9%, respectively. In the univariate analysis, a CPS of 20 or higher, first-line treatment, no history of cetuximab use, and the presence of irAEs was associated with better survival rates, whereas in the multivariate analysis, the first two factors were significantly associated with better survival. In this study, 16 of 20 cases had a CPS of 50 or higher, and 7 had a CPS of 90 or higher, indicating that a large number of high CPS cases were included, which is believed to have contributed to the results of this study.ConclusionIn patients with a CPS of 20 or higher, pembrolizumab can be administered as first-line treatment, with favorable expected therapeutic effects.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Biomarkers predictive of response to pembrolizumab in head and neck cancer
    Pfister, David G.
    Haddad, Robert, I
    Worden, Francis P.
    Weiss, Jared
    Mehra, Ranee
    Chow, Laura Q. M.
    Liu, Stephen, V
    Kang, Hyunseok
    Saba, Nabil F.
    Wirth, Lori J.
    Sukari, Ammar
    Massarelli, Erminia
    Ayers, Mark
    Albright, Andrew
    Webber, Andrea L.
    Mogg, Robin
    Lunceford, Jared
    Huang, Lingkang
    Cristescu, Razvan
    Cheng, Jonathan
    Seiwert, Tanguy Y.
    Bauml, Joshua M.
    [J]. CANCER MEDICINE, 2023, 12 (06): : 6603 - 6614
  • [42] Cisplatin Eligibility Issues and Alternative Regimens in Locoregionally Advanced Head and Neck Cancer: Recommendations for Clinical Practice
    Szturz, Petr
    Cristina, Valerie
    Gomez, Ruth Gabriela Herrera
    Bourhis, Jean
    Simon, Christian
    Vermorken, Jan B.
    [J]. FRONTIERS IN ONCOLOGY, 2019, 9
  • [43] A Review of Immunotherapy for Head and Neck Cancer
    Goetz, J. W.
    Rabinowits, G.
    Kalman, N.
    Villa, A.
    [J]. JOURNAL OF DENTAL RESEARCH, 2024, 103 (12) : 1185 - 1196
  • [44] Gene Therapy in Head and Neck Cancer
    Farmer, Zachary L.
    Kim, Edward S.
    Carrizosa, Daniel R.
    [J]. ORAL AND MAXILLOFACIAL SURGERY CLINICS OF NORTH AMERICA, 2019, 31 (01) : 117 - +
  • [45] Emerging drugs for head and neck cancer
    Wen, Yihui
    Grandis, Jennifer R.
    [J]. EXPERT OPINION ON EMERGING DRUGS, 2015, 20 (02) : 313 - 329
  • [46] Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era
    Hwang, Michael
    Seiwert, Tanguy Y.
    [J]. LANCET ONCOLOGY, 2021, 22 (04) : 413 - 415
  • [47] Immunotherapy for head and neck cancer: Recent advances and future directions
    Cramer, John D.
    Burtness, Barbara
    Ferris, Robert L.
    [J]. ORAL ONCOLOGY, 2019, 99
  • [48] Retreatment with nivolumab for patients with recurrent and/or metastatic head and neck cancer
    Wakasugi, Tetsuro
    Takeuchi, Shoko
    Ohkubo, Jun-ichi
    Suzuki, Hideaki
    [J]. ACTA OTO-LARYNGOLOGICA, 2022, 142 (02) : 206 - 212
  • [49] Immune Checkpoint Inhibitors Serve as the First-Line Treatment for Advanced Head and Neck Cancer
    Huang, Yan
    Zhou, Hong
    Zhao, Guangyong
    Wang, Meihua
    Luo, Judong
    Liu, Jun
    [J]. LARYNGOSCOPE, 2024, 134 (02) : 749 - 761
  • [50] The use of pembrolizumab monotherapy for the management of head and neck squamous cell carcinoma (HNSCC) in the UK
    Vasiliadou, Ifigenia
    Grose, Derek
    Wilson, Christina
    Thapa, Alekh
    Donnelly, Olly
    Lee, Elsa
    Leslie, Isla
    Karim, Mahwish
    Hartley, Andrew
    Partridge, Sarah
    Medlow, Katharine
    De Boisanger, James
    Metcalf, Robert
    Williamson, Andrew
    Haridass, Anoop
    Noble, David
    Mactier, Karen
    Walter, Harriet
    Ma, Ning
    De Winton, Emma
    Cohen, Jennifer
    Rayner, Lindsay
    Geropantas, Konstantinos
    Jankowska, Petra
    Mason, Jessica
    Moleron, Rafael
    Laws, Kirsten
    Ulahannan, Danny
    Nallathambi, Chandran
    Michaelidou, Andriana
    Nallamilli, Susanna
    Raouf, Sherif
    Palmer, Kieran
    Bienz, Maya
    Karet, Tracy
    Khalique, Saira
    Paterson, Claire
    Harrington, Kevin
    Bhide, Shreerang
    Kong, Anthony
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2024, 155 (05) : 883 - 893